https://www.selleckchem.com/pr....oducts/etomoxir-na-s
to CDs; however, the comparability between the various economic evaluation studies was limited due to the different outcome measures used. In addition, it remains unclear whether the additional health benefits of IODs outweigh the higher costs. This is largely dependent on the decision maker's valuation of oral health outcomes. Future research is encouraged to further elucidate patient willingness to pay for IODs and the societal return on investing in IODs more generally.The therapeutic efficacy of natural killer (NK) cells-ba
Like
Comment
Share
